Illustration of a healthy uterus with supportive microfluidic porous scaffolds

A Breakthrough for Uterine Health: Porous Scaffolds Offer New Hope for Intrauterine Adhesion Prevention

Soraya Malik monogram
Soraya Malik in Health & Wellness October 2026 • 4 min read.

"Revolutionary microfluidics technology paves the way for innovative treatments, offering a beacon of hope for women's reproductive health"


Intrauterine adhesions (IUAs), also known as Asherman's syndrome, present a significant challenge to women's reproductive health, often leading to infertility, recurrent miscarriages, and other serious complications. Current preventive measures have limitations, highlighting the urgent need for more effective solutions.

Now, a groundbreaking study introduces a novel approach: porous scaffolds engineered from biocompatible materials using advanced microfluidics. These scaffolds offer a unique combination of properties designed to prevent IUAs and promote tissue regeneration.

This article explores how these innovative scaffolds are created, their potential benefits, and the promising results they've demonstrated in preclinical studies, offering a new perspective on the future of uterine health and IUA prevention.

AI Search Multiple angles on this topic

Health Effects and Data Needs

The CDC’s Division of Reproductive Health monitors maternal and infant mortality and gathers data on morbidity and conditions that affect reproductive health. Intrauterine adhesions (IUAs) can form when scar tissue binds surfaces of the uterine cavity, often following surgery or infection. Reported effects include menstrual abnormalities, abdominal pain, infertility, recurrent pregnancy loss, and pregnancy-related complications. Women with IUAs after uterine surgery may also have light or absent menstruation, infertility, preterm delivery, or peripartum hemorrhage.

Recognizing and Treating Uterine Adhesions

Intrauterine adhesions have been described as a reproductive-age health problem that can impair physical, social, and psychological well-being. Their presentation ranges from no symptoms or an incidental finding to ceased menstruation and loss of reproductive function. Hysteroscopic treatment offers an opportunity to restore the symmetry of the uterine cavity; the cited clinical overview reports improvement in menstrual abnormalities and reproductive outcomes after removal of adhesions. A 2025 study describes examining risk factors, mechanisms, diagnosis, and medical-background influences in IUAs and Asherman syndrome.

How Do These Microfluidic Scaffolds Prevent Intrauterine Adhesion?

Illustration of a healthy uterus with supportive microfluidic porous scaffolds

The innovative porous scaffolds leverage the precision of microfluidics to create structures with specific properties that address the challenges of IUA prevention. Here's a breakdown of their design and function:

The process begins with carefully selecting biocompatible materials. Gelatin methacryloyl (GelMA) and sodium alginate (Na-alginate) form the base of these scaffolds, offering excellent biocompatibility and biodegradability.

  • Microfluidic Precision: Droplet microfluidics enables the creation of highly uniform and controlled porous structures.
  • Customizable Design: By adjusting the microfluidic parameters, researchers can fine-tune the scaffold's pore size, mechanical properties, and shape to match the uterine cavity.
  • Drug Delivery: The porous structure allows for the incorporation and controlled release of therapeutic agents, such as bFGF, to promote tissue regeneration and prevent adhesion.
  • Biocompatibility: GelMA and Na-alginate ensure the scaffold integrates well with the body's tissues, minimizing adverse reactions.
AI Search Multiple angles on this topic

Scaffold Materials and Delivery Strategies

A 2025 review of polysaccharide-based hydrogels reports that drug-containing scaffolds may be a suitable option for treating intrauterine adhesions after surgery. A systematic review of bioengineering in female reproduction lists hyaluronic-acid and gelatin-coated materials, as well as artificial polymer scaffolds made from polyglactin and polylactide, among materials used in this research area. Separately, research on microfluidic technology describes its potential for producing well-ordered porous polymer scaffolds through arrays of gas-in-liquid bubbles or liquid-in-liquid droplets. These sources describe developing approaches and materials rather than establishing a single proven scaffold treatment for IUAs.

Comparing PRP Delivery Approaches

A retrospective cohort study at a university hospital compared hysteroscopic subendometrial injection of platelet-rich plasma (PRP) with intrauterine PRP instillation for treating IUAs. The available source description identifies the objective and study design but does not provide comparative outcome figures, so it does not establish which approach was more effective. IUAs can involve fusion of injured opposing uterine walls, partially or completely obliterating the cavity or cervical canal. The cited clinical overview also characterizes IUAs as a major cause of secondary infertility and a substantial health and economic burden.

Preclinical studies have demonstrated the effectiveness of these scaffolds in preventing IUA formation and promoting endometrial regeneration. The scaffolds provide a physical barrier to prevent adhesion, while the controlled release of drugs stimulates tissue repair and reduces inflammation.

A Promising Future for Uterine Health

The development of porous scaffolds using microfluidics represents a significant advancement in the prevention and treatment of IUAs. These innovative devices offer a unique combination of biocompatibility, customizable design, and controlled drug delivery, addressing the limitations of current approaches.

AI Search Multiple angles on this topic

A Growing Research Field

A bibliometric study describes intrauterine adhesion research as an expanding body of academic work. It examines literature from the past two decades to identify major research domains and trends. The source description does not specify particular emerging domains or predict clinical breakthroughs, but it frames mapping the research landscape as a way to understand how the field is developing.

Symptoms and Reproductive Outcomes

IUAs form when injured opposing walls fuse, potentially narrowing or completely obliterating the uterine cavity or cervical canal. The cited systematic review identifies menstrual disturbances, cyclic pain, and reproductive disorders as the main clinical manifestations. A separate study set out to analyze menstrual conditions, recurrence factors, and pregnancy outcomes among 449 patients with IUAs after hysteroscopy. The source description gives the study population and aims but does not report its outcome findings.

While further research is needed to fully evaluate their long-term efficacy and safety in humans, preclinical studies have demonstrated promising results, suggesting that these scaffolds have the potential to significantly improve the reproductive health and quality of life for women affected by IUAs.

As research progresses, these microfluidic scaffolds may pave the way for even more sophisticated and personalized treatments for a wide range of uterine health conditions, marking a new era in women's healthcare.

What the scaffold evidence suggests, in plain terms

In a rat model, drug-loaded porous scaffolds were associated with new blood-vessel growth, cells entering damaged tissue, and endometrial repair. This supports a biological repair signal in that model, not proof of benefit in people.[1]

A separate description of a 3D-printed scaffold combines adipose-derived stem cells with PF-127 and GelMA, while another hydrogel report describes tissue adhesion as a feature for remaining in the uterine cavity. These are distinct design approaches, not evidence that one material or delivery method is established as best.[2] [3]

The porous structure is described as helping retain cells, and connected open pores as enabling ongoing drug release in vivo. Together, these features explain how scaffold architecture could support both cell presence and delivery, but do not by themselves establish clinical effectiveness.[1] [2]

How microfluidic scaffolds fit among related approaches

Microfluidic methods can generate arrays of uniform bubbles or droplets, and changing dispersed or continuous flow rates changes droplet size. This describes process control, not a demonstrated clinical outcome.[4]

Other prevention strategies have been evaluated against recurrence after adhesiolysis: pooled recurrence estimates were similar for no adjuvant, balloon, and IUD groups, while a separate guideline report found no difference between balloon and IUD groups. These comparisons concern existing approaches, not direct comparisons with porous scaffolds.[5] [6]

A meta-analysis reported reduced adhesion incidence and score with hyaluronic acid gel after intrauterine operations, whereas evidence reviews describe low or very low quality for some anti-adhesion studies and limited evidence for gels on reproductive outcomes. These findings underscore that evidence differs by intervention and outcome.[7] [8] [9]

What remains unanswered about scaffold performance

  • How do scaffold retention and drug release relate to the amount and timing of tissue repair? The sources describe retention, connected pores, and continuous release, but do not establish that relationship.[1] [2] [3]
  • Which scaffold materials and fabrication settings best balance uniform pores, drug loading, and repair? The sources describe multiple materials and flow-dependent droplet sizing, without identifying a best-performing combination.[4] [10]

Sources

  1. Porous scaffolds from droplet microfluidics for prevention of intrauterine adhesion. (doi.org, 2019)
  2. Microfluidic 3D-printed MSC-laden bioactive hydrogel for intrauterine adhesion prevention and endometrial regeneration (Materials Today Bio, 2025)
  3. Biodegradable and injectable curcumin-loaded hydrogel for the prevention of postoperative intrauterine adhesion (Frontiers in Bioengineering and Biotechnology, 2025)
  4. Microfluidic Technology for the Production of Well-Ordered Porous Polymer Scaffolds (2020)
  5. The epidemiology, clinical burden, and prevention of intrauterine adhesions (IUAs) related to surgically induced endometrial trauma: a systematic literature review and selective meta-analyses (pmc.ncbi.nlm.nih.gov)
  6. AAGL practice report: practice guidelines on intrauterine adhesions developed in collaboration with the European Society of Gynaecological Endoscopy (ESGE) (pmc.ncbi.nlm.nih.gov)
  7. Meta-analysis on the use of hyaluronic acid gel to prevent intrauterine adhesion after intrauterine operations (pmc.ncbi.nlm.nih.gov)
  8. Anti-adhesion treatment after hysteroscopy for women having difficulty becoming pregnant | Cochrane (www.cochrane.org)
  9. Anti-adhesion barrier gels following operative hysteroscopy for treating female infertility: a systematic review and meta-analysis (pmc.ncbi.nlm.nih.gov)
  10. Infertility treatment using polysaccharides-based hydrogels: new strategies in tissue engineering and regenerative medicine (2025)

About this Article -

Written with AI assistance from published research, and reviewed by the Mystum team. See our About page for more information.

This article is based on research published under:

DOI-LINK: 10.1016/j.actbio.2018.11.016, Alternate LINK

Title: Porous Scaffolds From Droplet Microfluidics For Prevention Of Intrauterine Adhesion

Subject: Molecular Biology

Journal: Acta Biomaterialia

Publisher: Elsevier BV

Authors: Yunlang Cai, Fangyuan Wu, Yunru Yu, Yuxiao Liu, Changmin Shao, Hongcheng Gu, Minli Li, Yuanjin Zhao

Published: 2019-01-01

Everything You Need To Know

1

How do these porous scaffolds work to prevent Intrauterine Adhesions (IUAs)?

Porous scaffolds are designed to prevent Intrauterine Adhesions (IUAs). They're created using microfluidics and made from biocompatible materials, specifically Gelatin methacryloyl (GelMA) and sodium alginate (Na-alginate). These scaffolds offer a physical barrier, preventing the uterine walls from sticking together and also allow for the controlled release of therapeutic agents, such as bFGF, to promote tissue regeneration. This dual action makes them effective in preventing and treating IUAs.

2

Why is microfluidics important in the creation of these scaffolds?

Microfluidics plays a crucial role in creating these porous scaffolds. Microfluidics enables the precise control over the scaffold's structure. This technology allows for the creation of uniform and customizable designs. Researchers can adjust microfluidic parameters to fine-tune the pore size, mechanical properties, and shape of the scaffold, ensuring it fits the uterine cavity and functions optimally. This level of precision is key to the scaffold's effectiveness in preventing Intrauterine Adhesions (IUAs).

3

Why are Intrauterine Adhesions (IUAs) a significant health concern?

Intrauterine Adhesions (IUAs), also known as Asherman's syndrome, are problematic because they can lead to infertility, recurrent miscarriages, and other severe complications. The current preventative measures are limited, making the development of effective solutions, such as porous scaffolds, extremely important. IUAs occur when the uterine walls stick together, which is what the scaffolds aim to prevent, thereby improving the chances of successful pregnancies and overall reproductive health.

4

What is the significance of Gelatin methacryloyl (GelMA) and sodium alginate (Na-alginate) in these scaffolds?

Gelatin methacryloyl (GelMA) and sodium alginate (Na-alginate) are vital because of their excellent biocompatibility and biodegradability. The porous scaffolds are made from these materials. Biocompatibility means that these materials are well-tolerated by the body, minimizing adverse reactions and ensuring the scaffold integrates well with the uterine tissues. Biodegradability ensures that the scaffold breaks down safely over time, leaving no harmful residues. This combination is essential for the scaffold's functionality and safety in preventing Intrauterine Adhesions (IUAs).

5

What role does bFGF play in this new approach to uterine health?

bFGF (basic Fibroblast Growth Factor) is a therapeutic agent incorporated into the porous scaffolds. The porous structure enables the controlled release of bFGF. This is significant because bFGF promotes tissue regeneration and reduces inflammation. This controlled release helps the uterine lining to heal and prevents the formation of Intrauterine Adhesions (IUAs), improving reproductive outcomes. The ability to deliver bFGF directly to the affected area enhances the effectiveness of the treatment.

Newsletter Subscribe

Subscribe to get the latest articles and insights directly in your inbox.